SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

Why It Matters

The findings reassure clinicians that sex alone should not dictate valve choice, while highlighting stroke and quality‑of‑life signals that may refine patient‑specific device strategies.

Key Takeaways

• 5‑year outcomes similar across valve types for both sexes.
• Women’s stroke rate lower with self‑expanding valve (0.9% vs 12%).
• Self‑care QoL higher for women using self‑expanding valve.
• Men’s mortality exceeds women’s (53.9% vs 43.7%).
• Valve choice should prioritize anatomy, not patient sex.

Pulse Analysis

Long‑term data from the SOLVE‑TAVI trial fill a critical gap in transcatheter aortic valve replacement (TAVR) research, offering the first five‑year head‑to‑head comparison of the Medtronic Evolut R self‑expanding system and the Edwards Sapien 3 balloon‑expandable platform. By enrolling 447 intermediate‑to‑high risk patients across Germany, the study provides robust evidence on durability, procedural safety, and clinical efficacy that extends beyond the typical 1‑ to 2‑year follow‑up windows seen in earlier trials. This depth of follow‑up is especially valuable as the TAVR market matures and clinicians seek confidence in device longevity.

A striking observation emerged among female participants: stroke rates were dramatically lower with the self‑expanding valve, and self‑care quality‑of‑life scores were nearly double those seen with the balloon‑expandable counterpart. While investigators caution that the stroke disparity may reflect trial‑specific procedural nuances—such as higher pre‑ and post‑dilation rates for balloon devices—the consistency of the self‑care signal suggests a possible link between lower transvalvular gradients and functional independence. These hypothesis‑generating findings align with similar trends reported in the SMART trial, prompting further investigation into sex‑specific hemodynamic benefits.

For practitioners, the practical takeaway is clear: valve selection should be anchored in anatomical suitability, vascular access, and procedural considerations rather than patient sex alone. However, the nuanced stroke and QoL data encourage a more individualized discussion with female patients, weighing the modest stroke risk reduction against other factors like device availability and operator experience. As longer‑term outcomes continue to accumulate, the industry can anticipate refined guidelines that integrate both hard clinical endpoints and patient‑centered quality‑of‑life metrics, ultimately driving more personalized TAVR strategies.